Salacia reticulata for Health & Longevity
Evidence Review created on 11/03/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Kothala Himbutu, Kotala Himbutu, Himbutu, Ponkoranti, Kadalazhinjil, Salacia, Salacia Root, Salcital
Motivation
Salacia reticulata (Kothala himbutu) is a woody climbing plant native to Sri Lanka and southern India whose roots and stems are sold as teas, extracts and capsules. Its main compounds slow the breakdown of starch and table sugar in the gut, the same principle used by an older class of diabetes drugs. That makes it of interest to people who want gentler blood sugar curves after meals without a prescription.
The plant has a long history in Ayurvedic and traditional Sri Lankan medicine for diabetes and excess weight, and it is widely sold in Japan as a health food product. Interest from people focused on healthy aging grew after a drug with the same mechanism was tested for its effect on lifespan in mice, raising the question of whether a plant source might act in a similar way.
This review examines the human, animal and laboratory evidence on Salacia reticulata for blood sugar control, body composition and healthy aging, together with its side effects, drug interactions, dosing, product quality and monitoring, to show what the evidence does and does not support.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists high-level narrative reviews on Salacia reticulata and its salacinol-type sugar-digestion inhibitors.
-
Salacia reticulata (Kothala himbutu) revisited; a missed opportunity to treat diabetes and obesity? - Medagama, 2015
A Sri Lankan physician’s critical review of laboratory, animal and human evidence on glucose and weight, including why HbA1c (glycated hemoglobin, a three-month blood glucose average) shifts in short trials are hard to interpret.
-
Anti-diabetic and Anti-hyperlipidemic Effects and Safety of Salacia reticulata and Related Species - Stohs & Ray, 2015
Covers glucose, lipid and safety data across S. reticulata, S. oblonga and S. chinensis, including rodent toxicology and liver-enzyme studies; the first author was affiliated with supplement marketer AdvoCare.
-
A review of antidiabetic active thiosugar sulfoniums, salacinol and neokotalanol, from plants of the genus Salacia - Morikawa et al., 2021
The discovering Japanese group’s account of the chemistry and pharmacology of salacinol-type compounds and their development into Japanese functional foods, written by researchers involved in that development.
-
Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity - Li et al., 2008
Argues the root acts beyond sugar digestion, on aldose reductase (converts excess glucose to sorbitol), pancreatic lipase (digests dietary fat) and a fat-breakdown gene switch, and notes rigorous human safety trials are lacking.
Only four items qualify. No content on Salacia reticulata was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io, and Life Extension Magazine mentions it only in passing, as a low-cost acarbose-like supplement within a broad article on heart attack risk factors (Faloon 2009); the herb is rarely covered in Western longevity media, so academic reviews fill the list.
Grokipedia
A broad encyclopedic overview of botany, traditional Sri Lankan uses, active compounds such as salacinol and kotalanol, and conservation concerns from overharvesting of wild plants.
Examine
Summarizes four human trials (199 participants), grading effects on blood glucose and HbA1c, and gives 240–1,000 mg taken with carbohydrate-containing meals as the studied dose, pooling S. reticulata and S. oblonga.
ConsumerLab
No ConsumerLab article on Salacia reticulata exists; the site search returns no review, product test or report dedicated to it.
Systematic Reviews
No systematic reviews or meta-analyses for Salacia reticulata were found on PubMed as of November 3, 2026.
Mechanism of Action
Salacia reticulata acts mainly inside the gut. Its thiosugar sulfonium compounds, chiefly salacinol, kotalanol, ponkoranol and neokotalanol, inhibit brush-border enzymes that release glucose from starch and table sugar: human maltase-glucoamylase (Sim 2010) and rat sucrase and isomaltase (Yoshikawa 2002). Slower digestion flattens the post-meal rise in glucose and insulin, the same principle as the drug acarbose (DailyMed acarbose label).
Secondary mechanisms, shown mostly in rodents and cells:
- Mangiferin: this root polyphenol inhibits aldose reductase (an enzyme converting excess glucose to sorbitol, implicated in nerve and eye damage) and acts as an antioxidant, per a review (Li 2008).
- Lipid pathways: PPAR-α (peroxisome proliferator-activated receptor alpha, a gene switch raising liver fatty-acid oxidation, i.e., fat breakdown) activation and pancreatic lipase (fat-digesting enzyme) inhibition may lower triglycerides, per a review (Stohs 2015).
- Fat cells: less fat-cell maturation in cultured cells and less fat accumulation in obese diabetic mice (Shimada 2010).
- Gut effects: undigested carbohydrate reaching the colon feeds bacteria, shifting microbiota toward bifidobacteria in a trial by extract maker FUJIFILM (Oda 2015); related S. chinensis raised GLP-1 (glucagon-like peptide-1, a gut hormone that boosts insulin release and satiety) (Kreitman 2021).
A competing view holds that only the gut-enzyme effect matters clinically and is modest; critics questioned the significance of single-meal glucose findings (Clemens 2005). Key pharmacological properties are uncharacterized: no human study reports half-life, tissue distribution, metabolism or CYP (cytochrome P450, the liver enzyme family that metabolizes drugs) pathways, so systemic rodent actions remain unconfirmed in people.
Historical Context & Evolution
Kothala himbutu has been used for centuries in Sri Lankan and Indian Ayurvedic medicine, mainly as root and stem decoctions, for diabetes, obesity, rheumatism and skin disorders, as summarized in a review (Medagama 2015). Its original intended use was thus the traditional management of what is now called type 2 diabetes.
Modern interest began when Japanese chemists isolated salacinol in 1997 and then kotalanol, a new class of alpha-glucosidase inhibitors (compounds that block the gut enzymes splitting starch and sugar into glucose); the group later established salacinol’s full structure (Yoshikawa 2002). Japan went on to market Salacia teas and tablets as functional foods for post-meal glucose, as the discoverers’ review describes (Morikawa 2021). In the 2000s Abbott tested S. oblonga extract in medical-food beverages (Heacock 2005; Williams 2007), while Sri Lankan physicians tested Kothala himbutu tea in type 2 diabetes (Jayawardena 2005).
Opinion evolved as the evidence type changed. Early claims rested on sugar-loaded rats; small human studies then reported lower post-meal glucose, and critics questioned whether single-meal effects were clinically meaningful (Clemens 2005). Longer placebo-controlled trials measuring HbA1c followed, and 2026 Korean trials added prediabetes and body-fat outcomes, both co-authored by extract supplier Daehan Chemtech (Baek 2026; Park 2026). Its consideration for health optimization is newer and indirect: acarbose, which shares the mechanism, extended mouse lifespan in the National Institute on Aging Interventions Testing Program (Harrison 2014). No long-term outcome trial has yet tested either the enthusiasts’ or the skeptics’ position.
Expected Benefits
High 🟩 🟩 🟩
Lower Fasting Glucose and HbA1c
Salacia reticulata modestly lowers fasting glucose and HbA1c by slowing carbohydrate digestion. RCTs (randomized controlled trials) from three independent groups agree: the Fernando group in Sri Lankan type 2 diabetes (Jayawardena 2005; Siribaddana 2023), Shivaprasad in Indian prediabetes (Shivaprasad 2013; sponsor Olive Lifesciences sells the extract), and Baek in Korean prediabetes, which also reduced post-glucose-load exposure (Baek 2026; extract supplier Daehan Chemtech co-authored). Trials were short (6 weeks to 3 months), and a review notes that Shivaprasad found no effect on the glucose tolerance test (Medagama 2015).
Magnitude: HbA1c 0.25 percentage points lower than placebo after 3 months in type 2 diabetes (8.19% vs 8.46%) (Siribaddana 2023); end-of-treatment HbA1c 6.29% vs 6.65% after placebo (Jayawardena 2005).
Medium 🟩 🟩
Improved Blood Lipids
In 29 adults with prediabetes and mild-to-moderate high cholesterol, 250 mg root-bark extract twice daily lowered LDL (low-density lipoprotein, the main cholesterol carrier linked to artery plaque) cholesterol versus placebo at weeks 3 and 6 (Shivaprasad 2013); a 12-week Korean trial lowered triglycerides (Baek 2026). Each lipid fraction rests on one small, industry-linked trial, and rodent mechanisms (lipase inhibition, PPAR-α activation) are unconfirmed in people. The related S. oblonga lowered triglycerides in chronic kidney disease (Singh 2015).
Magnitude: Direction only: LDL cholesterol (root-bark arm) and triglycerides fell significantly versus placebo; neither trial’s openly available report gives a between-group outcome figure, and the full texts are paywalled (Shivaprasad 2013; Baek 2026).
Modest Fat-Mass Reduction
In adults with overweight or obesity, a standardized extract twice daily for 12 weeks reduced fat mass measured by DXA (dual-energy X-ray absorptiometry, a body-composition scan) versus placebo, but the co-primary endpoint, body-fat percentage, did not differ (Park 2026). The trial was registered retrospectively and co-authored by supplier Daehan Chemtech. An open-label trial of the extract plus vitamin D reported larger weight loss, but the combination and lack of blinding make it indirect (Ofner 2013).
Magnitude: Total fat mass 482 g lower than placebo (95% CI, confidence interval, the range likely to contain the true effect: 58 to 907 g lower); body-fat percentage 0.30 points lower (95% CI −0.73 to 0.12), not significant (Park 2026).
Low 🟩
Kidney Function in Chronic Kidney Disease
In a 6-month randomized trial of 60 Indian patients with chronic kidney disease, the related S. oblonga stabilized creatinine clearance (a kidney filtration measure) and lowered CRP (C-reactive protein, an inflammation marker) versus placebo (Singh 2015). Evidence is indirect: a different species, with no S. reticulata kidney trial.
Magnitude: Direction only: creatinine clearance was stabilized compared with placebo (P = 0.04–0.05; P is the probability of a chance finding); the openly available report gives no between-group outcome figure, and the full text is paywalled (Singh 2015).
Speculative 🟨
Immune Function and Gut Microbiota
In 30 healthy Japanese men aged 50–60, 240 mg/day extract for 4 weeks raised T-cell (immune-coordinating white blood cell) proliferation and bifidobacteria versus placebo (Oda 2015, FUJIFILM-run). Unvalidated biomarkers only; no clinical immune outcome measured.
Longevity via Blunted Glucose Spikes
The drug acarbose, which shares the alpha-glucosidase mechanism, extended median lifespan 22% in male and 5% in female mice (Harrison 2014). No lifespan study of Salacia exists; the basis is mechanistic analogy only.
Reduced Bone Resorption
A single 500 mg dose of the related S. chinensis lowered post-meal CTX (C-terminal telopeptide, a bone-breakdown marker), tracking a rise in GLP-1 (Kreitman 2021). Single-meal biomarker data from a different species only.
Less Liver Fat
In obese diabetic mice, S. reticulata in the diet reduced liver fat accumulation and fat-cell enlargement (Shimada 2010). No human liver-fat study exists; the basis is animal data only.
Benefit-Modifying Factors
- Genetic polymorphisms: No pharmacogenetic study exists. Variants in SI (the sucrase-isomaltase gene, encoding one enzyme Salacia inhibits) already reduce sucrose digestion and could plausibly shrink any added benefit; this is inferred from mechanism, not tested.
- Baseline glycemia: Trials enrolled prediabetes or type 2 diabetes, with baseline HbA1c up to about 8.5% (Siribaddana 2023). Adults with normal glucose have less room for change; post-meal spikes on a glucose monitor show whether a target exists.
- Carbohydrate intake: The effect requires dietary starch or sucrose, so dosing alongside carbohydrate-containing meals is standard (Examine Salacia reticulata page). On very-low-carbohydrate diets little substrate remains to act on.
- Sex: No S. reticulata trial reports sex differences. With the related S. chinensis, hunger fell in women but not men (Hao 2017); acarbose extended lifespan more in male mice (Harrison 2014).
- Pre-existing conditions: Benefit is shown in prediabetes, type 2 diabetes and overweight; obese diabetic mice responded at both doses, lean mice only at the higher dose (Shimada 2010). Effects in people already on several glucose-lowering drugs may be smaller.
- Age: Trials enrolled adults of roughly 30–60 years; immune data come only from men aged 50–60 (Oda 2015). Adults over 65 are unstudied, so benefit at the older end is unknown.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no adverse event has been documented against placebo in S. reticulata trials from more than one research group; harm data come from short trials that did not systematically record symptoms.
Medium 🟥 🟥
No risk reaches Medium: no single controlled S. reticulata trial has recorded an adverse event in excess of placebo; the available harm signals are indirect, from related species, drug-class analogy, or animals.
Low 🟥
Gas, Bloating and Abdominal Discomfort ⚠️ Conflicted
Undigested carbohydrate ferments in the colon, producing gas, as with alpha-glucosidase inhibitor drugs. With S. oblonga, breath hydrogen rose and mild flatulence occurred (Collene 2005, Abbott-funded); S. reticulata trials reported no adverse events but did not record symptoms systematically (Shivaprasad 2013). Net: likely mild and dose-related.
Magnitude: Breath hydrogen excretion 60% greater than control meals with 1,000 mg S. oblonga, with mild flatulence; the source reports no symptom rate in either group (Collene 2005).
Hypoglycemia With Glucose-Lowering Drugs
Added to sulfonylureas (tablets that force insulin release) or insulin, extra glucose lowering may cause hypoglycemia (low blood sugar). In a 3-month RCT, glibenclamide doses fell on Salacia tea and rose on placebo, a non-significant trend (Jayawardena 2005); a Sri Lankan survey linked related S. prinoides to hypoglycemia (Dissanayake 2018).
Magnitude: Daily glibenclamide dose fell 1.89 mg on Salacia versus a 2.25 mg rise on placebo (P = 0.07); the trial reports no hypoglycemia rate in either group (Jayawardena 2005).
Speculative 🟨
Pregnancy Loss and Low Birth Weight
In pregnant rats, 10 g/kg root extract raised post-implantation (embryo) loss to 42–49% versus 5% and lowered birth weight (Ratnasooriya 2003). The dose far exceeds human intake; no human pregnancy data exist.
Chromosomal Damage Signal
An S. oblonga extract was weakly positive for chromosomal aberrations (structural chromosome damage) in human lymphocytes in vitro, but negative in bacterial, mouse and 90-day rat tests (Abbott-funded: Flammang 2006; Flammang 2007). Laboratory signal only.
Liver Enlargement and Altered Drug Metabolism
At 4.5% of diet, Salacia changed liver CYP activity in mice and inhibited CYP1A2 (a caffeine-clearing liver enzyme) in vitro (Yokotani 2013); high-dose S. oblonga enlarged rat livers (Rong 2008). Basis: nonhuman data only.
Risk-Modifying Factors
- Genetic polymorphisms: Congenital sucrase-isomaltase deficiency (inherited inability to digest sucrose and some starch) already causes gas and diarrhea; adding an alpha-glucosidase inhibitor could plausibly worsen symptoms. This is inferred from mechanism; no data exist.
- Baseline glucose: Near-normal glucose while on sulfonylureas or insulin leaves less margin before hypoglycemia; glibenclamide doses trended down during Salacia tea use (P = 0.07) (Jayawardena 2005).
- Sex: Pregnancy is the main sex-specific risk, based on rat fetal loss (Ratnasooriya 2003). High-dose S. oblonga enlarged livers more in male than female rats (Rong 2008); human trials have not analyzed adverse events by sex.
- Pre-existing conditions: Inflammatory bowel disease and intestinal obstruction contraindicate acarbose (DailyMed acarbose label); the shared gut mechanism makes caution with Salacia an inference. Cirrhosis (advanced liver scarring), also an acarbose contraindication, is a concern inferred from rodent liver enlargement (Rong 2008).
- Age: Older adults on insulin or sulfonylureas face higher hypoglycemia risk, per the American Diabetes Association (ADA) guideline, whose members earn nothing from Salacia (ADA Standards of Care 2026); no Salacia trial enrolled adults beyond about 65, so age-specific harm data are absent.
Key Interactions & Contraindications
Documented interactions:
- Sulfonylureas (glibenclamide/glyburide, glimepiride, gliclazide): additive glucose lowering. In a 3-month RCT, daily glibenclamide dose fell 1.89 mg with Salacia tea but rose 2.25 mg with placebo, a non-significant trend (P = 0.07) (Jayawardena 2005). Glucose checks and prescriber dose review mitigate hypoglycemia.
- Metformin: no interaction found; metformin dose changes did not differ between Salacia tea and placebo in the same RCT (Jayawardena 2005), and co-use showed no renal or liver deterioration (Siribaddana 2023).
Theoretical interactions (inferred from mechanism, not studied in humans):
- Insulin and meglitinides (short-acting insulin-releasing tablets: repaglinide, nateglinide): additive glucose lowering could cause hypoglycemia. Dextrose tablets, not table sugar, correct hypoglycemia when sugar digestion is blocked, as labeled for acarbose (DailyMed acarbose label).
- Alpha-glucosidase inhibitor drugs (acarbose, miglitol, voglibose): same mechanism; additive gas, bloating and diarrhea, plus further glucose lowering. Using both is redundant.
- GLP-1 receptor agonists (drugs mimicking GLP-1: semaglutide, liraglutide) and DPP-4 inhibitors (drugs blocking the GLP-1-degrading enzyme: sitagliptin): additive glucose lowering and gastrointestinal effects through overlapping gut-hormone pathways; glucose and tolerance tracking mitigates.
- CYP1A2 substrates (caffeine, theophylline, clozapine, tizanidine): CYP1A2 was inhibited in vitro and liver CYP activity shifted in mice at high doses (Yokotani 2013); raised levels could cause caffeine jitteriness or theophylline or clozapine toxicity. Monitoring drug effects mitigates.
- Over-the-counter digestive enzymes (amylase, pancreatin) and activated charcoal: may reduce Salacia’s effect by restoring carbohydrate digestion or binding it, inferred from the acarbose label (DailyMed acarbose label). Separating doses by 2 hours mitigates.
- Glucose-lowering supplements (berberine, cinnamon, chromium, gymnema, bitter melon, mulberry leaf, white kidney bean extract): additive glucose lowering; mulberry and white bean also block carbohydrate digestion, adding gas. Glucose tracking when stacking mitigates.
- Glucose-raising drugs (thiazide diuretics, i.e., drugs that increase urine output, such as hydrochlorothiazide; corticosteroids, i.e., anti-inflammatory steroid hormones such as prednisone): may offset Salacia’s effect, inferred from acarbose labeling (DailyMed acarbose label). Glucose tracking after starting or stopping them mitigates.
- Elective surgery: additive glucose lowering during fasting and anesthesia; stopping about 2 weeks beforehand is common practice for glucose-lowering herbs.
Populations who should avoid Salacia reticulata:
- Pregnancy (Avoid): inferred from rat data: root extract raised fetal loss and lowered birth weight (Ratnasooriya 2003); no human data.
- Breastfeeding: inferred from possible transfer of the root’s active compounds into breast milk, given their fetal toxicity in rats; no human data.
- Inflammatory bowel disease, colonic ulceration, partial or predisposed intestinal obstruction, chronic malabsorption: inferred from the acarbose contraindications for the same mechanism, since added gut gas may worsen these conditions (DailyMed acarbose label); no Salacia data.
- Cirrhosis: inferred from dose-related liver enlargement in rats given high-dose S. oblonga (Rong 2008) and from the acarbose contraindication (DailyMed acarbose label); no Salacia human data.
- Insulin or sulfonylurea users with recurrent or unrecognized hypoglycemia (level 2, below 54 mg/dL, per ADA Standards of Care 2026; ADA members earn nothing from Salacia) without glucose monitoring: inferred from additive glucose lowering (Jayawardena 2005).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Dosing with carbohydrate meals: dosing just before starch- or sugar-containing meals matches the mechanism (Examine Salacia reticulata page) and avoids glucose lowering on an empty stomach, limiting hypoglycemia risk with diabetes drugs.
- Low start with titration: protocols begin at 240 mg/day split across meals (Oda 2015) and rise to 500 mg/day (Shivaprasad 2013) after 1–2 weeks if tolerated, to limit gas and bloating.
- Glucose checks with diabetes drugs: sulfonylurea or insulin users check glucose during the first 2–4 weeks; below 70 mg/dL (3.9 mmol/L) is hypoglycemia per ADA Standards of Care 2026 (no ADA revenue tie to Salacia), prompting prescriber dose review.
- Dextrose on hand: glucose tablets, not table sugar, treat hypoglycemia when sugar digestion is blocked (DailyMed acarbose label); this prevents a slow, failed correction of low glucose.
- Pregnancy avoidance: stopping before conception attempts prevents exposure to the fetal-loss risk seen in rats (Ratnasooriya 2003).
- Pre-surgery pause: stopping about 2 weeks before elective surgery reduces perioperative hypoglycemia risk while fasting.
- Verified product: choosing species-identified, standardized, third-party-tested extracts reduces exposure to mislabeled species and contaminants; pharmacopeia-compliant tablets avoid poor disintegration, which some Japanese salacinol tablets showed (Kuribayashi 2024).
Therapeutic Protocol
Doses below are cited to their sources; other parameters without a citation (timing, titration, cycling) reflect common practice.
- Standardized extract: 500 mg/day as 250 mg root-bark extract twice daily for 6 weeks (Shivaprasad 2013; NCT01680211), or 500 mg/day standardized extract for 12 weeks in prediabetes (Baek 2026).
- Low-dose meal-split regimen: 240 mg/day hot-water stem-and-root extract: 60 mg before breakfast and lunch, 120 mg before dinner, for 4 weeks (Oda 2015).
- Traditional and food forms: Kothala himbutu tea daily for 3 months (Jayawardena 2005), or four extract biscuits twice daily as snacks (NCT02290925). Traditional decoctions are unstandardized.
- Dose range across sources: Examine gives 240–1,000 mg with carbohydrate meals (Examine Salacia reticulata page); single-meal studies of S. oblonga used 240–1,000 mg (Williams 2007; Heacock 2005).
- Competing approaches: whole-herb tea or decoction (Ayurvedic practice), standardized extracts (Japanese and Indian makers such as FUJIFILM and Olive Lifesciences), and prescription acarbose, 25–100 mg three times daily (DailyMed acarbose label), share the mechanism; none is established as superior.
- Popularizers: Sri Lankan Ayurvedic practitioners popularized the tea; Japanese functional-food makers, including FUJIFILM (Oda 2015), and the salacinol research group (Morikawa 2021) popularized standardized extracts.
- Time of day: taken immediately before or with the day’s carbohydrate-containing meals; the effect is meal-bound rather than dependent on time of day.
- Half-life: human half-life is uncharacterized. Salacinol-type compounds act on brush-border enzymes inside the intestine (Sim 2010), so closeness to the meal matters more than blood levels.
- Single vs split dosing: split doses matched to two or three meals follow the trial designs (Oda 2015; Shivaprasad 2013); a single daily dose covers only one meal.
- Genetic polymorphisms: no genotype-guided dosing exists; people with known sucrase-isomaltase deficiency may tolerate only low doses because of gas.
- Sex: no sex-specific dosing exists; women who are or may become pregnant are excluded because of rat fetal-loss data (Ratnasooriya 2003).
- Age: no age-specific dose exists; for older adults on glucose-lowering drugs, the lowest studied dose, 240 mg/day (Oda 2015), with glucose checks is the common starting point.
- Baseline biomarkers: trials enrolled baseline HbA1c from prediabetic levels to about 8.5% (Siribaddana 2023); with normal HbA1c, post-meal glucose on a monitor is the more responsive readout.
- Pre-existing conditions: in type 2 diabetes on sulfonylureas, drug doses may need lowering (Jayawardena 2005); bowel disease and cirrhosis are avoidance conditions.
Discontinuation & Cycling
- Duration: used continuously while a glucose goal persists; trials lasted at most 3 months per period (Siribaddana 2023), so lifelong use is unstudied.
- Withdrawal effects: none reported; post-meal glucose simply returns to its prior pattern because the effect is meal-bound.
- Tapering: not needed for Salacia itself. If sulfonylurea or insulin doses were lowered during use, glucose can rise after stopping, so those drugs are typically re-adjusted.
- Cycling: no evidence supports cycling; no loss of effect over time has been reported, and tolerance has not been studied.
- Planned stops: about 2 weeks before elective surgery and before attempting conception, as described under risk mitigation.
Sourcing and Quality
- Species identity: products labeled “Salacia” may contain S. reticulata, S. oblonga or S. chinensis, which differ in compound profile, per a review (Morikawa 2021). Labels naming species and plant part match trial material.
- Standardization: trial extracts quantified actives, e.g., 4.17 µg/mg salacinol and 2.26 µg/mg kotalanol (Oda 2015). Standardization to salacinol, neokotalanol or mangiferin indicates consistent potency.
- Plant part: root-bark extract lowered LDL and fasting glucose, whereas leaf extract lowered only fasting glucose, and only at week 6 (Shivaprasad 2013).
- Tablet quality: Japanese salacinol tablets varied in disintegration, and some failed after humid storage (Kuribayashi 2024). Cool, dry storage and pharmacopeia-compliant products reduce this risk.
- Third-party testing: USP (United States Pharmacopeia) or NSF (an independent product-certification body) certification is rare for Salacia; a certificate of analysis covering identity, heavy metals and microbes is the practical substitute.
- Reputable suppliers: clinically studied ingredients include Salcital from Olive Lifesciences (Shivaprasad 2013), FUJIFILM’s extract (Oda 2015) and Daehan Chemtech’s standardized extract (Baek 2026).
Practical Considerations
- Time to effect: post-meal glucose blunting occurs with the same meal; fasting glucose shifted by weeks 3–6 (Shivaprasad 2013) and HbA1c by 3 months (Jayawardena 2005).
- Common pitfalls: taking it without carbohydrates, confusing species, expecting large weight loss, and treating hypoglycemia with table sugar, whose digestion is blocked, instead of dextrose (DailyMed acarbose label, shared mechanism).
- Regulatory status (US): sold as a dietary supplement; makers are responsible for safety and labeling before marketing, and the FDA (US Food and Drug Administration) acts against adulterated or misbranded products after sale (FDA dietary supplements overview).
- Regulatory status (Japan): salacinol-containing tablets are sold as “foods with function claims” (Kuribayashi 2024).
- Cost and accessibility: not exceptionally expensive and widely available. Supplements are not reimbursed and acarbose is generic, so neither payers nor drug makers have a strong incentive to fund large Salacia trials, a structural reason the evidence remains small.
Interaction with Foundational Habits
- Sleep: none documented; no study measured sleep. Indirect, untested possibility: blunting dinner glucose spikes might smooth overnight glucose. A dinner dose can cause evening gas or bloating, so sensitive people may prefer earlier meals for dosing.
- Nutrition: potentiating with starch- and sucrose-rich meals; largely irrelevant on very-low-carbohydrate diets. Undigested carbohydrate feeds colonic bacteria, raising bifidobacteria (Oda 2015). Large sugar loads increase gas. No nutrient depletion has been reported.
- Exercise: none documented; no study exists. Indirect additive effect: post-meal walking also lowers glucose, so with sulfonylureas or insulin, exercise plus Salacia raises hypoglycemia risk, and glucose checks around longer sessions are common practice. No evidence of blunted training adaptation.
- Stress management: none documented; no cortisol data exist. Indirect: stress hormones raise glucose through liver output, which Salacia does not target, since it acts only on carbohydrate digestion in the gut.
Monitoring Protocol & Defining Success
Before starting, baseline testing establishes glycemic status and a reference for later change: HbA1c, fasting glucose and a lipid panel, plus, for those wanting post-meal data, one to two weeks of CGM (continuous glucose monitor, a skin sensor recording glucose every few minutes) readings on usual meals. Sulfonylurea or insulin users also note their recent hypoglycemia history.
Ongoing monitoring follows trial time frames: post-meal CGM or fingerstick checks during the first 1–2 weeks, fasting glucose and lipids at 6 weeks, HbA1c at 3 months, then every 6–12 months. Success means a smaller post-meal glucose rise and lower HbA1c or fasting glucose than baseline, without troublesome gas or hypoglycemia. No measurable change after 3 months suggests no meaningful effect for that person.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| HbA1c | 4.0–5.6% (standard reference range) | Expected to change: primary trial outcome | Glycated hemoglobin; reflects about 3 months of glucose; no fasting needed; repeat no sooner than 3 months |
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Expected to change | 8–12 hour fast; morning draw; pair with HbA1c |
| Post-meal glucose (CGM) | No established target; track peak rise and 2-hour return versus own baseline meals | Expected to change: direct readout of the mechanism | CGM = continuous glucose monitor; compare identical meals with and without a dose |
| LDL cholesterol | <100 mg/dL (standard reference range) | Expected to change | LDL = low-density lipoprotein; part of a standard lipid panel; pair with triglycerides |
| Triglycerides | <150 mg/dL (standard reference range) | Expected to change | 9–12 hour fast improves accuracy |
| Glucose during low-sugar symptoms | At or above 70 mg/dL per ADA Standards of Care 2026 | Safety check: low values change drug or Salacia dosing | Only for sulfonylurea or insulin users; ADA = American Diabetes Association (no revenue tie to Salacia), threshold from ADA Standards of Care 2026; conventional fasting reference range 70–99 mg/dL |
Qualitative markers:
- Gas, bloating or loose stools after dosed meals (tolerance)
- Post-meal energy and drowsiness
- Hunger and fullness between meals
- Shakiness, sweating or confusion suggesting hypoglycemia (for glucose-lowering drug users)
Emerging Research
- No ongoing trials: as of November 3, 2026, ClinicalTrials.gov lists no recruiting or active trial of S. reticulata (ClinicalTrials.gov search for Salacia); no pending result is positioned to change the conclusion soon.
- Completed biscuit trial: NCT02290925 (133 participants, phase 3, primary endpoint HbA1c) completed April 2017; posted and published results show HbA1c 0.25 points below placebo (Siribaddana 2023), as cited under benefits.
- Completed prediabetes trial: NCT01680211 (40 enrolled) completed June 2012, with no registry results posted; it was published as Shivaprasad 2013, reporting lower LDL and fasting glucose versus placebo.
- Body composition: the first DXA-based RCT found lower fat mass but unchanged body-fat percentage and was registered retrospectively (Park 2026); prospective replication could confirm or overturn the Medium grade.
- Glucose spikes in prediabetes: a 12-week Korean RCT reported lower glucose AUC (area under the curve, total glucose exposure) and higher 1,5-anhydroglucitol (a marker that falls with frequent spikes) (Baek 2026); independent replication would strengthen or weaken the High grade.
- Null and critical findings: a 90-day Indian study saw non-significant glucose and lipid changes (Radha 2009), and critics question single-meal relevance (Clemens 2005); larger null trials would weaken the case.
- Microbiome and immunity: a 4-week RCT showed bifidobacteria and T-cell shifts (Oda 2015); trials with clinical endpoints such as infection rates would test whether these matter.
- Bone and gut hormones: single-meal S. chinensis data show lower CTX and higher GLP-1 (Kreitman 2021); long-term bone-density trials would test relevance.
- Longevity analogy: acarbose’s mouse lifespan extension (Harrison 2014) motivates the hypothesis; no lifespan or aging-biomarker study of Salacia exists, and absent acarbose-like effects would weaken it.
- Safety gaps: rat fetal loss (Ratnasooriya 2003) and an in-vitro chromosomal signal (Flammang 2006) remain unreplicated; standard reproductive-toxicity studies could strengthen or remove these concerns.
Conclusion
Salacia reticulata is a woody climbing plant from Sri Lanka and southern India whose root and stem contain compounds that slow the digestion of starch and table sugar in the gut, working much like an older diabetes drug. For health-focused adults who want to soften blood sugar spikes after meals, it offers a plant source of that drug’s mechanism.
The most consistent finding is a modest drop in fasting blood sugar and in the long-term blood sugar marker in people with early or established type 2 diabetes, seen by separate research groups in Sri Lanka, India and Korea. Effects on blood fats and body fat are smaller and rest on one or two small studies, while links to immunity, gut bacteria, bone and lifespan come from short marker studies, animals or comparison with the related drug.
The main expected side effects are gas and bloating, and blood sugar can fall too low when the herb is combined with insulin or certain diabetes tablets. Animal work raises a concern about pregnancy.
The evidence base is small and short-term, much of it funded or co-written by companies that make or sell the extract, and products vary in species, plant part and strength. No study has measured long-term health outcomes or aging itself. For people whose blood sugar is already normal, the expected gain is smaller and less certain than for those with early blood sugar problems.